Note: Descriptions are shown in the official language in which they were submitted.
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
SOLID DISPERSION OF A NEUROKININ ANTAGONIST
The present invention relates to novel pharmaceutical compositions comprising
a neurokinin
antagonist, in particular an acylaminoalkenylene amide.
More specifically, the present invention relates to a solid dispersion
comprising (4R)-4-[N'-
methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-
enoic acid
N-[(R)-epsilon-caprolactam-3-yl]-amide or a salt or solvate thereof as
pharmaceutical
ingredient and a carrier. Said pharmaceutical ingredient is also known as N-
[(R,R)-(E)-1-
(3,4-dichlorobenzyl)-3-(2-oxoazepan-3-yl) -carbamoyl]-allyl-N-methyl-3,5-bis
(trifluoromethyl)-benzamide and has the chemical structure of formula I
F
F \ C F
-~
F, C ic iC O 1
/ \ ~ ll
F F H CN CN NH
3 H
CI 0
CI
The compound of formula I, especially the semihydrate thereof, is useful in
the treatment of a
number of conditions associated with neurokinins (substance P, neurokinin A,
neurokinin B),
for example (i) functional motility disorders of the viscera including those
associated with
visceral hypersensitivity and/or altered motor responses (including
electrolyte/water
secretion), for example functional bowel disorders and functional
gastrointestinal disorders,
such as irritable bowel syndrome (IBS), constipation, diarrhoea, functional
dyspepsia, gastro-
oesophageal reflux disease, functional abdominal bloating, and functional
abdominal pain,
other conditions associated with visceral hypersensitivity such as post-
operative visceral pain,
visceral smooth muscle spasms, and irritable bladder and other functional
bowel disorders
(not necessarily associated with visceral hypersensitivity or abnormal motor
responses) as
described in international patent application WO 03/66062, or (ii) urinary
bladder disorders
"such as urinary incontinence, which may be for example, urge incontinence,
stress
incontinence, mixed urge/stress incontinence, or neurogenic incontinence
(unstable detrusor
and detrusor hyperreflexia, decreased bladder compliance, sensory urgency,
bladder-related
visceral pain) as described in international patent application WO 05/39563.
The invention is
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
2
of particular importance for the treatment of irritable bowel syndrome (IBS),
especially
diarrhoea- predominant IBS, and functional dyspepsia (FD). A method for the
preparation of
the compound of formula I is described in international patent application WO
98/07694,
the contents of which are incorporated herein by reference.
This compound presents highly specific difficulties in relation to
administration generally and
the preparation of galenic compositions in particular, including in particular
problems of
drug bioavailability and variability in inter- and intra-patient dose
response, necessitating
development of a non-conventional dosage form with respect to the practically
water-
insoluble properties of the compound.
It has now been found that (4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-
benzoyl)-amino]-4-
(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide
can be
formulated as a solid dispersion, giving an advantageous physical and chemical
stability and
superior bioavailability profile.
In a first aspect the present invention provides a solid dispersion comprising
(4R)-4-[N'-
methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-
enoic acid
N-[(R)-epsilon-caprolactam-3-yl]-amide or a pharmaceutically acceptable salt
or solvate
thereof and a carrier.
The term "solid dispersion" as used herein is understood to mean a system in a
solid state
that comprises at least two components, wherein one component is dispersed
substantially
evenly throughout the other component or components. This includes solid or
glassy
solutions i.e. the dispersion of the components is such that the system is
chemically and
physically uniform or homogenous throughout or consists of one phase (as
defined in
thermodynamics). A "solid dispersion" may comprise a co-precipitate or co-melt
of an active
ingredient and a carrier medium, wherein the active ingredient is dispersed
substantially
evenly throughout the carrier system. The active ingredient may be present in
a glassy
amorphous state or in fine crystalline dispersed form. It may be present as a
mixture of
amorphous and crystalline forms. The term solid dispersion may also encompass
systems
which consist of more than one phase. That means the active ingredient may
exist in multiple
phases such as a pure drug phase and/or in drug rich phases and/or drug poor
phase. In such
multi-phase systems there also may be phases without drug existing. The term
"solid
dispersion" as used herein also encompasses eutectic mixtures of the active
ingredient. Solid
dispersions, including solid or glassy solutions are well known and well
documented in the
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
3
prior art, e.g. A. T. M. Serajuddin "Solid Dispersion of Poorly Water-Soluble
Drugs: Early
Promises, Subsequent Problems and Recent Breakthroughs" J. Pharm. Sci. 88:1058-
1066
(1999); C. Leuner and J. Dressman "Improving drug solubility for oral delivery
using solid
dispersions" European Journal of Pharmaceutics and Biopharmaceutics 50:47-60
(2000) or
Chou and Riegelman, J. Pharm. Sci. 60, 1281s. (1971).
Throughout this specification and in the claims that follow, unless the
context requires
otherwise, the word "comprise", or variations such as "comprises" or
"comprising", should
be understood to imply the inclusion of a stated integer or step or group of
integers or steps
but not the exclusion of any other integer or step or group of integers or
steps.
The compound of formula I includes all pharmaceutically acceptable
isotopically-labelled
forms thereof wherein one or more atoms are replaced by atoms having the same
atomic
number, but an atomic mass or mass number different from the atomic mass or
mass number
usually found in nature. Examples of isotopes suitable for inclusion in the
compounds of the
invention include isotopes of hydrogen e.g. 2H and 3H, carbon e.g. "C,13C
and14C, chlorine
e.g. 36CI, fluorine e.g.'$F, iodine e.g. 123I and'uI, nitrogen e.g.13N and'5N,
oxygen e.g.15O,
170 and 180, and sulfur e.g. S.
Certain isotopically-labelled forms of the compound of formula I, for example
those
incorporating a radioactive isotope, are useful in drug and/or substrate
tissue distribution
studies. The radioactive isotopes tritium (3H) and carbon-14 (14C) are
particularly useful for
this purpose in view of their ease of incorporation and ready means of
detection. Substitution
with heavier isotopes such as deuterium (2H) may afford certain therapeutic
advantages that
result from greater metabolic stability, for example increased in vivo half-
life or reduced
dosage requirements, and hence may be preferred in some circumstances.
Substitution with
positron emitting isotopes, such as "C,18F,150, and 13N can be useful in
Positron Emission
Topography (PET) studies for examining substrate receptor occupancy.
Isotopically-labelled forms of the compound of formula I can generally be
prepared by
conventional techniques known to those skilled in the art or by processes
analogous to those
described in the accompanying examples using an appropriate isotopically-
labelled reagent in
place of the non-labelled reagent previously used.
In a second aspect the present invention provides a pharmaceutical composition
comprising
of a solid dispersion, said solid dispersion comprising (4R)-4-[N'-methyl-N'-
(3,5-
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
4
bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-
[(R)-epsilon-
caprolactam-3-yl]-amide or a pharmaceutically acceptable salt or solvate
thereof and a
carrier.
In a third aspect the present invention provides a method of treating a
subject suffering from
a disorder treatable with a neurokinin antagonist comprising administering a
therapeutically
effective amount of a pharmaceutical composition comprising a solid
dispersion, said solid
dispersion comprising (4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-
amino]-4-(3,4-
dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide or a
pharmaceutically acceptable salt or solvate thereof and a carrier to a subject
in need of such
treatment.
In a fourth aspect the present invention provides a method of treatment of a
subject suffering
from (i) gastrointestinal disorders, especially diarrhoea-predominant IBS and
functional
dyspepsia, (ii) urinary bladder disorders, especially urge incontinence, or
(iii) respiratory
diseases, especially asthma. comprising administering a therapeutically
effective amount of a
pharmaceutical composition comprising a solid dispersion, said solid
dispersion comprising
(4R)-4-[N'-methyl-N' -( 3,5-bistrifluoromethyl-benzoyl)-amino]-4-( 3,4-
dichlorobenzyl)-but-2-
enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide or a pharmaceutically
acceptable salt or
solvate thereof and a carrier to a subject in need of such treatment.
The solid dispersion of the present invention may be prepared by a number of
methods.
In a first method, the drug substance or active ingredient is dissolved in a
solvent or a solvent
mixture with one or more carrier. Some or all excipients (e.g. anti-sticking
agents, inert filers,
surfactants, wetting agents, pH modifiers or additives) may also be present in
the solvent or
solvent mixture dissolved or in a suspended or swollen state. The resulting
feed solution or
suspension may be dried by spray drying or by applying a spray granulation
process to form
a solid dispersion. The term spray drying refers to processes which involve
the atomization of
the feed suspension or solution into small droplets and rapidly removing
solvent from the
mixture in a processor-chamber where there is a strong driving force for the
evaporation of
the solvents (i.e. hot dry gas or partial vacuum or combinations thereof). The
term spray
granulation refers to processes where the solvent solution or suspension is
sprayed onto
suitable chemically and physically inert filler, i.e. Lactose pray dried or
Mannitol using
typically two-way or three-way nozzles.
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
In a second method, the feed solution or suspension is atomized and dried in
the processor
chamber of a spray dryer or a fluidized spray drier to form primary particles
which are
subsequently agglomerated in a fluid bed.
5 In a third method, the feed solution or suspension is dried by being
atomized into a processor
chamber of a fluid bed-type processor or a pan-coater which is charged with
inert filler
material. During drying the filler becomes agglomerated and/or coated and/or
layered by the
solid dispersion. A bottom spray mode or a top spray mode maybe used,
preferably a bottom
spray mode.
In a fourth method the solid dispersion is prepared by melting the drug
substance and/or the
carrier. Atomization and resodification of the molten dispersion is done in a
suitable fluid
bed processor (spray-congealing method). Alternatively a typical melt-
granulation process in
a heatable high-shear mixer is used.
In a fifth method, the feed solution or suspension is dried and/or dried and
chopped down at
elevated temperature and/or partial vacuum for example in a rotavapor-like
processor or
paddle dryer-type processors.
In a sixth method, solid dispersions are prepared by melting the drug
substance and/or the
carrier using a melt extruder.
In a seventh method solid dispersions are prepared by melting drug substance
and/or the
carrier in presence of a filler material wherein the particles are
agglomerated and/or coated
using a melt extruder.
In an eighth method solid dispersions are prepared by dissolving the drug
substance using a
solvent or a low melting material (for example: a polymer, plasticizer, wax,
surfactant) and
then mixing it into a carrier using a melt extruder.
In a ninth method solid dispersions are prepared by dissolving the drug
substance using a
solvent and drying it under reduced pressure, for example by using sealing
elements before
and after a vacuum port in the melt extruder.
In a tenth method solid dispersions are prepared by precipitation e.g. by
rapid mixing of the
feed solution or suspension with C02, or any other non-solvent/anti-solvent.
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
6
Suitable solvents for the solvent evaporation methods are alcohols such as
ethanol, methanol,
n-propanol, iso-proponal and butanol. Ketones such as acetone and methyl
ethylketone and
various other solvents like methylene chloride. Mixtures of these solvents may
also be used.
The solvent or solvent mixture may also contain up to 40% water in order to
increase the
swelling of selected polymeric carrier in the feed and thus to finally
optimize the dispersion
grade of the product (= solid dispersion).
The solid dispersions of the invention may be further processed into tablet,
or capsule form
or may be processed into multiparticular systems e.g. minitablets or pour-into
mouth
granulates or oral powders for constitution. Another possibility could be to
disperse the solid
dispersion in a suitable diluent in combination with other excipients (i.e. re-
crystallization/precipitation inhibiting polymers, taste-masking components
etc.) to give a
ready-to-use suspension formulation for paediatric treatment with limited in-
use stability.
In one embodiment of the present invention there is provided a solid
dispersion comprising
(4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl )-amino]-4-( 3,4-
dichlorobenzyl )-but-2-
enoic acid N-[(R)-epsilon-caprolactam-3-yl)-amide or a pharmaceutically
acceptable salt or
solvate thereof, and a polymeric carrier as a carrier.
Suitable polymeric carriers include water-soluble polymers, preferably a
cellulose derivative
such as hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC) or
polyvinylpyrrolidone (PVP) or copovidone (copolymer of I -vinyl-2-pyrrolidone
and vinyl
acetate). Good results may be obtained using HPMC with a low apparent dynamic
viscosity,
e.g. from about 0.01 cps to about 100 cps as measured at 20 C for a 2% by
weight aqueous
solution, e.g. from about 0.01 cps to about 50 cps, preferably from about 0.01
cps to about
20 cps, for example HPMC 3 cps. HPMC is well-known and described, for example,
in the
Handbook of Pharmaceutical Excipients, Second Edition, Pharmaceutical Society
of Great
Britain and American Pharmaceutical Association, 1994, pages 229 to 232, the
contents of
which are incorporated herein by reference. HPMC, including HPMC 3 cps, is
available
commercially under the trade mark Pharmacoat 603 from the ShinEtsu company.
PVP is
available, for example, under the trade mark Povidone (Handbook of
Pharmaceutical
Excipients, pages 392-399), and a PVP having an average molecular weight
between about
8,000 and about 50,000 Daltons is preferred, e.g. PVP K30.
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
7
Suitable polymer carriers also include polymers which show a pH-dependant
swelling and
thus may slow down or avoid drug release from the solid dispersion in gastric
environment
but swell or dissolve in intestinal juice. Examples of these polymers that are
applied for
enteric coating of tablets include the cellulose derivatives hydroxyl-propyl
methylcellulose
acetate succinate (HPMCAS), e.g. Aqoat MF or HF and
hydroxypropylmethylcellulose
phthalate (e.gHPMCP-.HP50 or HPMC-HP55). Suitable polymer carriers also
include a
copolymer formed from monomers selected from the group consisting of
methacrylic acid,
methacrylic acid esters, acrylic acid and acrylic acid esters, e.g. as those
known and
commercially available under the trade mark Eudragit from R6hm Pharma GmbH.
An
especially preferred polymer is the 1:1 or 1:2 copolymer formed from monomers
selected
from the group consisting of methacrylic acid and methacrylic acid lower alkyl
esters, such as
the 1:1 or 1:2 copolymer formed from methacrylic acid and methyl methacrylate.
The 1:1
copolymers are available under the trade mark Eudragit L, the 1:2 copolymers
are available
under the trade mark Eudragit S. A particularly preferred polymer is the 1:1
copolymer of
methacrylic acid and the acrylic acid ethyl ester as known and commercially
available under
the trade mark Eudragit L 100-55. The enteric polymers may also be used in
combination
with polymers that are non-resistant against gastric juice (e.g. HPMC or PVP)
in order to
allow to optimize locally available drug concentrations in the GIT and thus
optimize the
bioavailability.
In another embodiment the polymeric carrier comprises:
(i) hydroxypropylcellulose (HPC) or a derivative thereof. Examples of HPC
derivatives
include those having low dynamic viscosity in aqueous media, e.g. water, e.g.
from
about 0.01 cps to abut 400 cps, e.g. from about 0.01 cps to about 150 cps as
measured
in a 2% aqueous solution at 25 C. Preferred HPC derivatives have a low degree
of
substitution, and an average molecular weight e.g. between about 5000 and
about
200,000 Daltons, e.g. between about 50,000 and about 150,000 Daltons. Examples
of
HPC available commercially include Klucel LF, Klucel EF and Klucel JF from
the
Aqualon company; and Nisso HPC-L available from Nippon Soda Ltd;
(ii) a cyclodextrin, for example, a beta-cyclodextrin or an alpha-
cyclodextrin. Examples of
suitable beta-cyclodextrins include methyl-beta-cyclodextrin; dimethyl-beta-
cyclo-
dextrin; hyrdroxypropyl-beta-cyclodextrin; glycosyl-beta-cyclodexterin;
maltosyl-beta-
cyclo-dextrin; sulfo-beta-cyclodextrin; sulfo-alkylethers of beta-
cyclodextrin, e.g. sulfo-
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
8
C[1-4]-alkyl ethers. Examples of alpha-cyclodextrins include glucosyl-alpha-
cyclodextrin and maltosyl-alpha-cyclodextrin;
(iii) a polyethylene glycol (PEG). Examples include PEGs having an average
molecular
weight between 1000 and 9000 Daltons, e.g. between about 1800 and 7000, for
example PEG 2000, PEG 4000 or PEG 6000 (Handbook of Pharmaceutical Excipients,
pages 355-361);
(iv) a polymethycrylate (not just gastric-resistant); and
(v) a polyvinyl alcohol polymer and co-polymers thereof with PVP or other
polymers.
In another embodiment the carrier is a non polymeric carrier comprising low
molecular
weight substances which can form an amorphous glass such as saccharoses e.g.
mannitol,
sorbitol or substances like urea.
The carrier may further comprise one or more surfactants or wetting agents,
for example a
non-ionic, ionic, anionic or amphoteric surfactant. Examples of suitable
surfactantsfwetting
agents include polyoxyethylene-polyoxypropylene co-polymers and block co-
polymers
known, for example, under the trade marks Pluronic or Poloxamer ,
polyoxyethylene-
sorbitan-fatty acid esters including mono- and tri-lauryl, palmityl, stearyl
and oleyl esters of
the rype known under the trade name Tween , polyoxyethylene fatty acid esters
including
polyoxyethylene stearic acid esters of the type known under the trade name
Myrj , poly-
oxyethylene alkyl ethers known under the trade mark Brij , sodium alkyl
sulfates and
sulfonates, and sodium alkyl aryl sulfonates, water soluble tocopheryl
polyethylene glycol
succinic acid esters (TPGS), polyglycerol fatty acid esters, alkylene polyol
ethers or esters,
polyethylene glycol glyceryl fatty acid esters, sterols and derivatives
thereof, transesterified,
polyoxyethylated caprylic-capric acid glycerides, sugar fatty acid esters, PEG
sterol ethers,
phospholipids, salts of fatty acids, fatty acid sulfates and sulfonates, salts
of fatty acids, fatty
acid sulfates and sulfonates, medium or long-chain alkyl, e.g. C6-C18,
ammonium salts, bile
acid or salt thereof; for example cholic acid, glycolic acid or a salt, e.g.
sodium cholate and
polyoxyethylene mono esters of a saturated CIo to Czz fatty acid.
In a further embodiment, the present invention provides a pharmaceutical
composition
comprising a solid dispersion, said solid dispersion comprising(4R)-4-[N'-
methyl-N'-(3,5-
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
9
bistrifluoromethyl-benzoyl)-aminoj-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-
[(R)-epsilon-
caprolactam-3-yl]-amide or a pharmaceutically salt thereof, a polymeric
carrier and a pH
modifiers such as acids, bases or buffers which may retard or enhance the
swelling of the
polymeric carrier in the GIT and thus may allow to target the drug release
into the desired
location. In addition conventional additives such as fillers, disintegrants,
anti-oxidants,
binders or anti-sticking agents may be part of the solid dispersion itself.
When these additives
are included as part of the dispersion they may be dissolved or suspended or
mixed into the
feed from which the solid dispersion is formed or alternatively be used as
starter material
(filler) in e.g. pan-coaters or fluid bed processors.
Suitable pH modifiers include but are not limited to citric acid., lactic acid
succinic acids and
bases like sodium acetate, calcium oxide, sodium hydroxide and buffer systems.
Suitable filler (or diluent) materials include but are not limited to, water-
soluble or water-
insoluble compounds such as lactose, sucrose, amylose, dextrose, mannitol and
inositol,
xylitol, microcrystalline cellulose, but preferably lactose, mannitol or
microcrystalline
cellulose. Microcrystalline cellulose is available commercially under the
trade mark Avicel ,
Pharmacel , Emcocell , Vivapur , preferably Avicel , available e.g. from FMC
Corporate
(Handbook of Pharmaceutical Excipients, pages 84-87). The fillers may also be
used in form
of rough more or less spheric particles like beads or pellets ; Cellets , ,
Celsphere which are
preferred starting materials for coating and layering technology. Suitable
filler and anti-
sticking agents also include colloidal Slicon Dioxide like Aerosil 200 or
Talc.
Examples of pharmaceutically acceptable disintegrants include, but are not
limited to,
starches; clays; celluloses; alginates; gums; cross-linked polymers, e.g.
cross-linked polyvinyl
pyrrolidone or crospovidone, e.g., POLYPLASDONE XL from International
Specialty
Products (Wayne, NJ); cross-linked sodium carboxymethylcellulose or
croscarmellose
sodium, e.g., AC-DI-SOL from FMC; and cross-linked calcium
carboxymethylcellulose; soy
polysaccharides; and guar gum.
The pharmaceutical compositions of the present invention may include
additional excipients
that are commonly employed in the preparation of dosage forms, such as
disintegrants,
lubricants, glidants, binders and fillers.
Examples of pharmaceutically acceptable lubricants and pharmaceutically
acceptable glidants
include, but are not limited to, colloidal silica, magnesium trisilicate,
starches, talc, tribasic
calcium phosphate, magnesium stearate, aluminium stearate, calcium stearate,
magnesium
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
carbonate, magnesium oxide, polyethylene glycol, powdered cellulose, glyceryl
behenate,
stearic acid, hydrogenated castor oil, glyceryl monostearate, and sodium
stearyl fumarate.
Examples of pharmaceutically acceptable binders include, but are not limited
to, starches;
5 celluloses and derivatives thereof, e.g., microcrystalline cellulose, e.g.,
AVICEL PH from
FMC (Philadelphia, PA), hydroxypropyl cellulose hydroxylethyl cellulose and
hydroxyl-
propylmethyl cellulose METHOCEL from Dow Chemical Corp. (Midland, MI);
sucrose;
dextrose; corn syrup; polysaccharides; and gelatin.
10 Examples of pharmaceutically acceptable fillers and pharmaceutically
acceptable diluents
include, but are not limited to, confectioner's sugar, compressible sugar,
dextrates, dextrin,
dextrose, lactose, mannitol, microcrystalline cellulose, powdered cellulose,
sorbitol, sucrose
and talc.
The pharmaceutical compositions of the present invention may further include
additives or
ingredients, such as antioxidants (e.g. ascorbyl palmitate, butyl hydroxy
anosole (BHA),
butyl hydroxy toluene (BHT), tocopherols, propyl gallate and fumaric acid),
antimicrobial
agents, enzyme inhibitors, stabilizers (e.g. malonic acid), and/or preserving
agents.
The active ingredient may be present in an amount by weight of the composition
of about
0.01 % to about 80%; for example, in an amount by weight of about 0.01% to
about 80%,
0.1% to about 70%, such as 1%% to 60%, for example 2%, 5%, 10%, 20%, 30%, 40%,
50%, or 60%.
In the solid dispersion according the invention the weight ratio
carrier:pharmaceutical
ingredient (i.e. (4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-
4-(3,4-
dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide or a
salt or solvate
thereof) is 1:0.01 to 1:0.8, preferably 1:0.2 to 1:0.8.
The carrier, preferably polymeric carrier may be present in an amount from
about 0.1 % to
99.99% by weight of the composition.
When a plasticizer or surfactant is present, it may generally be present in an
amount of from
about 0.01% to about 50%, for example from about 1% to about 30% by weight,
e.g. 5%
to 20% by weight of the composition.
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
11
When a disintegrant is present in the pharmaceutical composition, it may be
generally be
present in an amount from about 1% to about 30% by weight of the composition,
from
about 5 % to about 10% to about 20% by weight of the composition.
When a filler is present, it may generally be present in an amount of from
about 0.01 to
about 99% by weight of the composition, e.g. from about 0.S to about 70% by
weight, such
as about 30%, 40% or S0% to about 60% by weight of the composition.
When a lubricant is present, it may generally be present in amounts from about
0.1 % to
about 5% by weight of the composition; whereas, the glidant, e.g., may be
present in an
amount from about 0.1% to about 10% by weight of the composition.
When additives, for example antioxidants, are present they may generally
comprise about
O.OS-S%, preferably 0.0S-1 /a by weight of the composition.
When pH modifying agents is present they may generally comprise about 0.05-20%
by
weight of the composition.
When required, the solid dispersions of the invention are preferably
compounded in unit
dosage form, e.g. as a tablet, a capsule or a multi-particulate system such as
granules or
granulates or a powder, for administration. Where the composition is in unit
dosage form,
each unit dosage will suitably contain from 0.1 and 1S0 mg active agent, for
example 0.1 mg,
1 mg, S mg, 10 mg, 1S mg, 2S mg, S0 mg, or 100 mg, e.g. between S and 100 mg
of the
active agent. Such unit dosage forms are suitable for administration 1 to S
times daily
depending upon the particular purpose of therapy, the phase of therapy and the
like.
Multiparticulate systems (i.e. minitablets) have shown to further reduce the
amounts of
typically highly hygroscopic disintegrants needed (with respect to their
larger surface area)
and may therefore have the potential of higher physical stability with respect
to lower water
uptake properties compared to monolithic dosage forms.
The dosage form used, e.g. a tablet, minitablets, beads, pellets, granules,
granulates or
powder may be coated, for example using an enteric coating. Suitable coatings
may comprise
but are not limited to cellulose acetate phthalate;
hydroxypropylmethylcellulose phthalate; a
polymethyacrylic acid copolymer, e.g. Eudragit L or Eudragit S; or hydroxyl-
propyl
methylcellulose acetate succinate, e.g. Aqoat MF or HF.
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
12
Unit doses of the pharmaceutical composition of the invention are preferably
compartmentalised in a suitable blister pack to avoid moisture uptake inducing
crystal
formation and negatively affecting the stability of the composition generally.
This is
particularly important when the composition contains hydroscopic substances
such as certain
disintegrants.
The pharmaceutical compositions of the invention exhibit especially
advantageous properties
when administered orally; for example in terms of consistency and high level
of
bioavailability obtained in standard bioavailability trials. Such trials are
performed in
animals, e.g. rats or dogs or healthy volunteers using chromatographic
methods, e.g. HPLC.
The invention is illustrated in the following non-limiting examples.
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
13
EXAMPLES
In these examples "Compound A" is micronised (4R)-4-[N'-methyl-N'-(3,5-
bistrifluoro-
methyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-
caprolactam-
3-yl]-amide semihydrate.
A control formulation comprising the components listed in Table 1 below is
prepared as a
powder blend in a hard gelatine capsule.
TABLE 1
Component Mass
m HK
Compound A (active in redient 20.0
Lactose (filler) 49.0
Crospovidone disinte rant 10.0
Sodium lau I sulfate surfactant 20.0
Aerosil 200 (glidant) 0.5
Magnesium stearate (lubricant) 0.5
Example 1
Spray-dried solid dispersions
Solid dispersions 1A and 1C to 1K are manufactured in a Buechi-Minispary
apparatus.
1A, 1D, lE, 1F and solid dispersion 1G-1K are prepared by dissolving Compound
A in a 1:1
mixture of acetone and ethanol (abs). For solid dispersion C a 1:1 mixture of
acetone and
ethanol 94% den. (= ethanol quality with water and isopropanol) is used.
When a clear solution has formed, the other components listed in Tables 2 and
3 are added
into this mixture to give a feed-suspension or -solution. Typical solid to
liquid ratios in these
feeds are 1:5 to 1:7. The feed is atomized into a hot nitrogen gas atmosphere
of a spray dryer
to remove the solvents at a product-temperature around 90 C. The solid
dispersion is
collected as powder from the processor.
Solid dispersion 1B is prepared on the Pilot spray dryer Niro-Mobile Minor. A
1:1 mixture of
acetone and ethanol 94% den. (= ethanol quality with water and isopropanol) is
used.
When a clear solution has formed, HPMC is added into this mixture to give a
feed-
suspension. After adding of the polymer the feed is vigorously stirred for al
least 1 hour.
Subsequently it is passed through an IKA-mill (Pilot SN1102) for wet-milling.
The resulting
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
14
feed is atomized into the hot nitrogen of the spray drier to remove the
solvents at a product-
temperature of approx. 90-100 C. The dry solid dispersion is collected as
powder on the
cyclone discharge valve.
TABLE 2
Component 1A 1B 1C 1D 1E 1F
Compound A 20% 40% 60% 80% 40% 20%
(active in redient
HPMC-3cps 80% 60% 40% 20% 55% 70%
(polymeric carrier)
Myrj 59 5%
(surfactant)
Poloxamer 188 10%
(surfactant)
TABLE 3
Component 1G 1H ii 1K
Compound A 80% 40% 60% 20%
(active in redient
PVP K30 20% 60% 40% 80%
(polymeric carrier)
Some of those solid dispersions are blended with the excipients listed in
Table 4 or 5 and
then the blended mixture is compressed into tablets (T) or filled into hard
gelatin capsules
(H).
TABLE 4
Component 1L 1M 1N 1P
Tablet tablet 2x tablets tablet
Solid dispersion 100 mg IA 50 mg 1B 62.5 mg 1B 166.65 mg IC
(20%) (40%) 40% 60 0
Lactose 210.8 mg 175.5 mg 156.25 mg 274.35mg
filler
Sodium carboxy- 80 mg 18.75 mg 25.0 mg 50.0 mg
methyl starch
disinte rant
Colloidal silica 6.0 mg 3.75 mg 3.75 mg 4.0 mg
(lubricant)
Magnesium stearate 3.2 mg 2.0 mg 2.5 mg 5.0 mg
(lubricant)
The mass of Compound A contained in tablets/capsules 1L, 1M, 1N and 1P is 20
mg, 20 mg,
25 mg and 100 mg respectively.
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
t5
TABLE 5
Com onent 1 1R 1S
Tablet Hard gel caps tablet
Solid dispersion 50mg 1E 125 mg 1F 166.7 mg 1J
(407o) 20 0 60 0
Lactose 175.5 mg 125 mg 275.3 mg
(filler)
Sodium carboxymethyl 18.75 mg - 150.0 mg
starch disinte rant
Colloidal silica 3.75 mg - 4.0 mg
(lubricant)
Magnesium stearate 2.0 mg - 4.0 mg
(lubricant)
The mass of Compound A contained in tablets/capsules 1Q, 1R and 1S is 20 mg,
25 mg and
100 mg respectively.
The dissolution rate of some of the tablets/capsules is determined giving the
results shown in
TABLE 6 below. In each case the tablet/capsule is added to a solution
containing 1000 mL of
0.1N HCI and 0.3% Tween 20, 50 rpm paddle, 37 C.
TABLE 6
Time Control 0 1L o 1N o 1 0 1R o
20min 63.5f 10.8 80.2 5.5 n.d. - 91.2 4.4
30min 69.4 11.9 90 3.7 98.6 1.5 83 1 100.9 1.1
60min 74.4 13.6 94 0.3 101.2 0.5 87 0.5 101.2 0.5
Where n.d. = not determined
Table 6 shows that a significant increase in the dissolution rate of the solid
dispersions is
observed in comparison to the control.
Solid dispersions and tablets are stored at 25 C and 60% relative humidity in
closed and
open containers and at 40 C and 75% relative humidity in closed and open
containers.
However in each case no change in crystal structure is observed over 3 months
as measured
by differential scanning calorimetry (DSC) and X-ray powder diffraction
(XRPD). This
indicates that the solid dispersions remain amorphous even under accelerated
conditions (i.e.
40 C/ 75% r.h. open).
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
16
Super-saturation-studies
The in-vitro dissolution of the HPMC-based solid dispersion 1B (Component 113)
and that of
the enteric HPMC-P based solid dispersion 2D (Component 2D) were studied in
different
media and compared to the crystalline-hemihydrate or the amorphous compound A.
TABLE 7
Compd A crystalline Compd A-amorphous Component 1B
hemih drate
Compound A (mg/mi) - 4mg/mi = 100% release
Medium Time Concentration Concentration Concentration
[mg/mi] m ml m ml
SGF 10 min 0.000 0.491 1.817
30 min 0.000 0.000 1.675
60 min 0.000 0.000 1.407
180 min 0.000 0.000 0.000
FaSSIF 10 min 0.000 0.102 0.191
30 min 0.000 0.063 0.258
60 min 0.000 0.009 0.240
180 min 0.000 0.000 0.048
FeSSIF 10 min 0.062 0.531 1.378
30 min 0.054 0.575 1.279
60 min 0.056 0.048 0.711
180 min 0.044 0.049 0.086
SGF:= Simulated Gastric Fluid, FaSSIF/FeSSIF:= Fasted/Fed State Simulated
intestinal Fluid
In-vitro dissolution of the Component 1B is significantly superior compared to
the
hemihydrate or the amorphous compound A which confirms the solid dispersion
formulation
principle for this compound. In addition it is seen that the active compound A
has a strong
tendency to precipitate rapidly upon dissolution. It is expected that this
precipitated fraction
has low/no bioavailability. Surprisingly, the solid dispersion system 1B
clearly delays that
precipitation and indicates a stabilizing effect on the dissolved compound.
TABLE 8
Component 2D
Compound A m ml - 4mg/mi = 100% release
Medium Time Concentration
m ml
SGF 10 min 0.000
30 min 0.000
60 min 0.000
180 m i n 0.000
Buffer pH7 10 min 0.668
30 min 4.173
60 min 2.706
180 min 1.986
SGF:= Simulated Gastric Fluid
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
17
The solid dispersion system 2D (Component 2D) made with the enteric polymer
HPMC-P
(see table 9, example 2) does not release the active compound in gastric fluid
(SGF). Due to
that the rapid precipitation of compound A in the gastric environment can be
avoided. The
solid dispersion system 2D performance very well at a neutral pH at which 100%
of the drug
is dissolved within 30 minutes indicating enteric polymers a promising option
to reduce or
avoid gastric precipitation of compound A.
Example 2
Spray granulated solid dispersions manufactured in fluid bed processors
Solid dispersions 2A to 2D are prepared using the components listed in Table 9
below.
Compound A is dissolved in a 1:1 mixture of acetone and ethanol mixture to
form a clear
solution. Subsequently, the polymeric carrier is suspended into that mixture.
Typical liquid to
solid ratios are 1:5 to 1:7. An inert filler material (e.g. an Lactose) and an
anti-sticking agent
(e.g.-Aerosil0 200 ) are blended and fluidised in a warm process air stream in
the lab scale
fluidized bed processor (AeromaticT1'') and the feed is atomized via a top
spray two-fluid
nozzle into the processor causing the filler to get agglomerated and coated by
the solid
dispersion while evaporating the solvents. Typical product temperatures are 20-
50 C. The
solid dispersion is collected from the product container of the processor as
free-flowing
granules or granulates.
TABLE 9
Component 2A 2B 2C 2D 2E
Compound A (active in red. 30% 30% 27.3% 30% 30%
HPMC (polymeric carrier) 40% 40 0 36.4%
HPMC-P (HP-50) 40% 40%
(functional carrier)
Lactose (filler) 27% 27%
Mannitol SD200 (filler) 27% 27%
Cel hereO SCP100 (filler) 32.7
AerosilO 200 (anti-sticking 3.0 3% 3.6 3% 3%
a ent
Some of the solid dispersion granulates are further processed to tablets or
capsules as final
dosage form. This is achieved by blending the solid dispersion granulates with
the excipients
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
18
listed in Table 10 and then compressing the blended mixture into tablets (T)
or filling hard
gelatin capsules (H).
TABLE 10
Component 2F 2G 2H 2J 2K
Solid dispersion 83.3 mg 2A 83.3 mg 2B 100 mg 7 83.3 mg 2D 333.33 mg 2B
27.3a 300 300
(30%) (30%)
Lactose (filler) - - - - 108.167mg
Microcrystalline 187.5 mg 187.5 mg 170.8 mg 187.5 mg -
cellulose (filler)
Sodium carboxy- - - - - 35.0 mg
methyl starch
disinte rant
Crospovidone 10.0 mg 10.0 mg 10.0 mg 10.0 mg 15.0 mg
disinte rant
Colloidal silica - - - - 5.0 mg
(lubricant or glidant?)
Magnesium stearate 2.2 mg 2.2 mg 2.2 mg 2.2 mg 3.5 mg
(lubricant)
The mass of Compound A contained in tablets/capsules 2F, 2G, 2H and 2J is 25
mg but in
and 2K it is 100 mg.
The relative dissolution behaviour of some of the tablets/capsules is
determined giving the
results shown in TABLE 11 below. In each case the tablet/capsule is added to a
solution
containing 1000 mL of O.1N HCI and 0.3% Tween 20, 50 rpm paddle, 37 C.
TABLE 11
Time 2F 2G % 2H % ZJ %
30min 71.0 1.1 53.6 1.5 70.0:t 2.2 78.0:t 3.6
60min 78.3 1.1 55.3 1.4 77.9=-1.9 78.7-t 2.3
75min 81.4 0.7 56.7=-1.1 83.2 1.4 79.1 2.2
Solid dispersions and tablets are stored at 25 C and 60% relative humidity in
closed and
open containers and at 40 C and 75% relative humidity in closed and open
containers.
However in each case no change in crystal structure is observed over 3 months
as measured
by differential scanning calorimetry (DSC) and X-ray powder diffraction
(XRPD). This
indicates that the solid dispersions remain amorphous even under accelerated
conditions (i.e.
40 C/ 75% r.h. open).
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
19
Example 3
Melt extruded solid dispersions
Compound and A and HPMC are blended and turned into a solid dispersion by melt
extrusion.
Tablets containing 25 mg amorphous Compound A as a ground solid dispersion,
187.7S mg
microcrystalline cellulose, 10 mg Crospovidone and 2.25 mg magnesium stearate
are
prepared in accordance with Example 1. These are melt extruded to give solid
dispersions 3A
and 3B. Those solid dispersions contain the components listed in Table 12
below.
TABLE 12
Component 3A 3B
Compound A 25 0 50 a
HPMC (carrier) 75% 50%
Solid dispersions and tablets are stored at 25 C and 60% relative humidity in
closed and
open containers and at 40 C and 75% relative humidity in closed and open
containers.
However in each case no change in crystal structure is observed over 3 months
as measured
by differential scanning calorimetry (DSC) and X-ray powder diffraction
(XRPD). This
indicates that the solid dispersions remain amorphous even under accelerated
conditions (i.e.
40 C/ 75% r.h. open).
Example 4
Bioavailability studies
Material and Methods. Comparative bioavailability studies are performed
according to Swiss
Animal Welfare regulations, using adult male beagle dogs (stock animals
weighing between 9
and 15 kg) originating either from Marshall Farms (North Rose, USA) or from
Harlan
(France). The dogs are fasted overnight before dosing and for an additional 5
to 6 hours after
receiving their dose. The animals receive 300 to 350 g of standard pelletted
dog chow every
day. At least eight animals are used per dosage form, and whenever possible,
dogs from the
same group are re-used in subsequent experiments, using a crossover or latin
square study
design, in order to obtain a relative intraindividual comparison.
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
Dosing of capsule and tablet formulations of Compound A is performed orally by
deep
throat deposition, followed by a rinse with 20 mL water, to be swallowed.
Blood samples are
collected from a fore-leg vein (V. cephalica) into heparinized polypropylene
syringes before
and up to 48 hours post dose. Usually up to 12, exceptionally up to 15 blood
samples are
5 collected from each dog to obtain a precise profile of the drug levels over
time. Plasma is
collected after centrifugation at 2150 g, and stored frozen pending analysis.
After thawing,
protein precipitation and reconstitution of the samples using methanol, the
samples are
subjected to HPLC/tandem mass spectrometry analysis (atmospheric pressure
chemical
ionization interface) with a lower limit of quantification of 1.0 ng/mL.
The PK parameters after oral dosing of different tablet formulations and a
control capsule
give the following results (compare Table 13 below):
(a) Solid dispersion formulations reach high peak levels relatively early,
with an average
tmax between 1 and 1.5h, followed by a rapid decline, however, plasma levels
remain
close to or above the limit of quantification at 24 hours post dose, in some
animals
even after dosing of only 20 mg per dog.
(b) Sometimes, especially in the high dose group, a second peak was observed
24 hours
after dosing of solid dispersion formulations, in most cases lower than the
first peak,
and in some dog individuals more pronounced than in others; the reason for
this
second peak is still unclear, especially since this second peak could not be
reproduced
in the medium dose dog group, with increased sampling points around 24 hours.
(c) Trend of non-linearity of PK was obvious, here of decreasing Cmax/dose and
AUC/dose with increasing dose: strict data comparison may only be performed
within
the same dose level.
Within the same dose level:
(a) Solid dispersion formulations show an about twofold higher bioavailability
compared
to the control capsule with micronised drug substance in a standard powder
blend on
one hand as well as to the melt extrusion tablet 3A with 30% drug loading on
the
other hand.
(b) Addition of surfactant did not show a positive effect on oral
bioavailability of solid
dispersion formulations in the fasted dog model.
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
21
(c) Drug loading within a range of 20-40%, the choice of the polymeric carrier
(HPMC,
PVP) as well as the procedure of manufacture (spray granulation, spray drying)
had
no relevant influence on bioavailability of the drug substance given as solid
dispersion
to fasted dogs.
Solid dispersion formulations are rapidly absorbed and are excellent means to
increase the
bioavailability of Compound A in the fasted dog model.
TABLE 13
Nominal Tmaz Cmax Cmax/dose* AUC (0-48 hr) AUC(0-48h)/dose;
dose (hr) (ng/mL) (ng/mL)/(mg/kg) (ng/mL)*h (ng/mL)*h/(mg/kg)
Control 20 mg 1.5 721 546 385 285 2623 1584 1397 811
1L 20 mg 1.13 1483 636 901 321 5505 2413 3361 1261
1M 20 mg 1.38 1692 859 996 438 6135 2663 3627 1346
_1Q 20 mg 1.00 1219 # 779 723 t 422 4871 2394 2875 1240
1R 50 mg 1.2 1920 995 384 200 11600 4180 2320 839
lp 100 mg 1.5 2368 654 270 81.2 17461 10433 1996 1170
1S 100 mg 1-1.5 1876 789 212 85.5 15553 10493 1826 1375
2K 100 mg 1-4 1981 1110 227 125 16327 7303 1893 876
2F 25 mg 1.09 1440 544 766 289 4950 1950 2633 1037
1N 25 mg 1.06 1620 555 768 263 5870 2330 2782 1104
3A 25 mg 1.5 836 516 398 246 2790 1540 1329 733
*data dose-normalized to 1 mg/kg, assuming dose-linearity
By comparing the Control formulation at 20 mg dose with the solid dispersion
formulations
(1L, 1M, 1Q) Cmax and AUC were significantly higher for the solid dispersion
based
formulations.
Example 5
Minitablets with spray granulated solid dispersion
Some of the solid dispersion granulates are further processed to minitablets
as final dosage
form or as an intermediate product that can be further processed (i.e. coated,
capsule filling).
This is achieved by blending the solid dispersion granulates with the
excipients listed in Table
14 and then compressing the blended mixture into small (2mm in diameter)
minitablets .
The weight of one minitablet is circa 8 mg with a dose of 0.5 mg active
compound. To
deliver a 25 mg dose for instance, 50 minitablets can be filled into one hard
gelatine capsule
on a suitable capsule filling machine .
Table 14
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
22
Ingredient mg/tablet
S ra anulated solid dispersion 192.30
Lactose anhydrous 183.70
Crospovidone XL 20.00
Magnesium stearate 4.00
Total Final blend 400.00
In the given example the amount of the disintegrant Crospovidone XL is with 5%
rather low
and completely sufficient to achieve excellent dissolution properties for a 25
mg dose of
active compound. Table 15 shows the release profile for this dosage form with
0% (batch 1),
5 % (batch 2) and 10 % Crospovidone (batch 3).
Table 15:
Time batch 1 batch 2 Batch 3
0 0 0 0
5 76.4 46.6 3.3
91.6 94.1 21.1
30 91.7 92.6 63
45 89.8 89.8 82.3
60 84.8 85.5 90.3
75 83.2 82 91
The excellent maintenance of the release properties for the minitablets.with
even lower
10 (compared to the normal tablets) disintegrant concentrations are beneficial
for and even
distribution in the gastrointestinal tract in-vivo. Additional functional
coating (i.e. enteric
coating) should allow for more site specific delivery of the drug.
Example 6
15 Dispersion of the spray granulated solid dispersion in an aqueous medium
for paediatric drug
delivery
For paediatric applications liquid dosage forms (i.e. syrups, suspensions) are
preferable with
respect to patient compliance. In case of compound (4R)-4-[N'-methyl-N'-(3,5-
bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-
[(R)-epsilon-
caprolactam-3-yl]-amide application of the solid dispersion obtained through
example 2 in
an aqueous medium has turned out to be feasible if dosing of the freshly
prepared suspension
occurs within a three hours time interval. The aqueous medium should comprise
i.e. of a 6
%(w/w) HPMC or 6% (w/w) PVP, 6% sodium carboxymethyl cellulose, HPMCAS
solution to prevent early precipitation of the compound. Additionally taste
masking
CA 02672402 2009-06-11
WO 2008/077591 PCT/EP2007/011293
23
excipients (flavours, sweeteners) could be added to increase the acceptance by
the patient. It
has be found that Hydroxypropylcellulose (HPC) in the aqueous medium can
accelerate re-
crystallization/precipitation and should therefore been avoided.
Method of preparation:
1. Put required amount of water in a beaker of adequate size, add the
appropriate amount of
e.g. HPMC or PVP and stir vigorously until polymer is dissolved.
2. Add the solid dispersion slowly into the vortex of the stirred water and
continue stirring
after the powder addition is finished for further 15-30 minutes.
'10 A nearly clear, viscous solution is formed, very fine Aerosil particles
from the solid dispersion
may remain visible in the solution/suspension.
If required add additional taste masking excipients (flavor) and ensure that
the ready- to- use
suspension will be taken within 3 hours.
Chemical and physical in-use stability of differently concentrated (from
2mg/ml to 30 mg/ml
compound) suspension prepared out of the spray granulated solid dispersion
formulations
has turned out to be sufficient as can be seen from table 16 for a 4 hours
time interval.
Physical stability of the suspensions (re-crystallization/precipitation) was
checked under a
polarized light microscope and was appropriate as well.
Table 16:
Concentration Content Compound Degradation product Degradation product
[mg/ml] / Testing [%] each [%] sum [%]
timepoint at room
temperature [h]
Start * . 99.8 <0.1 <0.1
30mg/ml / 2h 100.3 <0.1 <0.1
30mg/ml / 4h 99.2 <0.1 <0.1
3 mg/ml /2h 99.3 <0.1 <0.1
3mg/ml / 4h 99.0 <0.1 <0.1
2mg /ml /2h 99.2 <0.1 <0.1
2mg/ml / 4h 99.7 <0.1 <0.1
